Common Contracts
6 similar null contracts by Salient Surgical Technologies, Inc., BIND Therapeutics, Inc, Precision Therapeutics Inc, Zogenix, Inc.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144...BIND Therapeutics, Inc • August 12th, 2013 • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, GE Capital Equity Investments, Inc. (“Holder”) is entitled to subscribe for and purchase eight thousand (8,000) shares of fully paid and nonassessable Series B Convertible Preferred Stock of BIND Biosciences, Inc., a DE corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series B Convertible Preferred Stock, $0.0001 par value per share, and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged.
WARRANT TO PURCHASE 200,000 SHARES OF SERIES A PREFERRED STOCKZogenix, Inc. • September 3rd, 2010 • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase Two Hundred Thousand (200,000) shares of fully paid and nonassessable Series A Preferred Stock of Zogenix, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series A Preferred Stock and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged.
WARRANT TO PURCHASE 166,667 SHARES OF SERIES E CONVERTIBLE PREFERRED STOCKSalient Surgical Technologies, Inc. • May 19th, 2008 • Electromedical & electrotherapeutic apparatus • New York
THIS CERTIFIES THAT, for value received, Oxford Finance Corporation (“Holder”) is entitled to subscribe for and purchase One Hundred Sixty-Six Thousand Six Hundred and Sixty-Seven (166,667) shares of fully paid and nonassessable Series E Convertible Preferred Stock of Salient Surgical Technologies, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series E Convertible Preferred Stock, $0.01 par value per share, and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged; provided, however, in the event all outstanding Prefer
WARRANT TO PURCHASE 42,425 SHARES OF SERIES E CONVERTIBLE PREFERRED STOCKSalient Surgical Technologies, Inc. • May 19th, 2008 • Electromedical & electrotherapeutic apparatus • New York
THIS CERTIFIES THAT, for value received, GE Capital Equity Investments, Inc. (“Holder”) is entitled to subscribe for and purchase Forty-Two Thousand Four Hundred and Twenty-Five (42,425) shares of fully paid and nonassessable Series E Convertible Preferred Stock of Salient Surgical Technologies, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series E Convertible Preferred Stock, $0.01 par value per share, and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged; provided, however, in the event all outstanding Preferred
WARRANT TO PURCHASE 154,545 SHARES OF SERIES E CONVERTIBLE PREFERRED STOCKSalient Surgical Technologies, Inc. • April 25th, 2008 • Electromedical & electrotherapeutic apparatus • New York
THIS CERTIFIES THAT, for value received, GE Capital Equity Investments, Inc. (“Holder”) is entitled to subscribe for and purchase One Hundred Fifty-Four Thousand Five Hundred and Forty-Five (154,545) shares of fully paid and nonassessable Series E Convertible Preferred Stock of Salient Surgical Technologies, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series E Convertible Preferred Stock, $0.01 par value per share, and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged; provided, however, in the event all outstand
WARRANT TO PURCHASE 181,818 SHARES OF SERIES B CONVERTIBLE PREFERRED STOCKPrecision Therapeutics Inc • August 24th, 2007 • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Hundred Eighty-One Thousand Eight Hundred Eighteen (181,818) shares of fully paid and nonassessable Series B Convertible Preferred Stock of Precision Therapeutics, Inc., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series B Convertible Preferred Stock and any stock into which such Preferred Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged.
